


Mobile Knowledge node	English Sitemap	Help Center
		
Summary		
fund		
Key words		
Classification number		
Knowledge network		
Citation network		
Associate Author		
similar article		
Related Fund Literature		

(Accepted version) Online release time: 2020-03-09 17:19:08

Preliminary study of hydroxychloroquine sulfate in treating common coronavirus disease (COVID-19) patients in 2019

Chen Jun Liu Danping Liu Li Liu Ping Xu Qing in Xia Lu Lingyun Huang Dan Song Shuli Zhang D an money Zhiping Li Tao Shen silver Zhong Lu Hongzhou

Department of Infection and Immunology, Shanghai Public Health Clinical Center

Export / Reference share it Create Citation Tracking

Abstract: Objective: To evaluate the efficacy and safety of hydroxychloroquine sulfate in the treatment of patients with common coronavirus disease (COVID-19) in 2019. Methods: Thirty confirmed COVID-19 patients who were hospitalized in Shanghai Public Health Clinical Center from February 6 to 25, 2020 were collected. Patients were randomly assigned 1: 1 to the experimental and control groups. The control group received conventional treatment, and the test group received oral chlorochloroquine sulfate (400 mg, 1 time / d for 5 days) on the basis of conventional treatment. The indexes of the negative rate of nucleic acid of throat swab virus on the 7th day of treatment were compared between the two groups. The study was approved by the Ethics Committee of Shanghai Public Health Clinical Center and registered (NCT04261517). Results: During the treatment, one patient in the test group developed severe. On the 7th day after enrollment, 13 patients (86.7%) in the test group and 14 patients (93.3%) in the control group were negative for pharynx swab virus nucleic acid ($P > 0.05$). During the 2-week visit, all subjects' throat swab nucleic acid tests turned negative. The test group's throat swab nucleic acid turned negative on the 4th (1-9) days after admission and the control group was There was no significant difference between 2 (1 to 4) days ($U = 83.5, P > 0.05$). The body temperature returned to normal on day 1 (0 to 2) after admission, and the body temperature returned to normal on day 1 (0 to 3) after admission. In imaging, 5 cases in the test group (33.3%) and 7 cases in the control group (46.7%) showed progress in the review after 3 days of admission, and all patients showed improvement in the subsequent review. In the experimental group and the control group, 4 (26.7%) and 3 (20.0%) patients had transient diarrhea and abnormal liver function ($P > 0.05$). Conclusion: At present, the prognosis of patients with common COVID-19 is good. It is difficult to compare the efficacy of the drug with the main endpoints of viral negative rate and exacerbation rate. Carrying out subsequent research needs to identify more suitable populations and endpoint events, and fully consider the feasibility of experiments such as sample size. reduction

Fund: Shanghai Science and Technology Commission (20431900103); Fudan University First-Class University and First-Class Discipline Construction Project (IDF162005); Zhejiang University New Coronavirus Pneumonia Emergency Scientific Research Project (2020XGZX030); Shanghai Public Health Clinical Center New Coronavirus Special projects in scientific research institutes (2020YJKY01); Shanghai Key Specialty Infectious Diseases Project (shslczdk01102); Shanghai "Yingyuanxinxing" Medical Talent Project (2019-72);

Keywords: Severe Acute Respiratory Syndrome Coronavirus 2; 2019 Coronavirus Disease; New Coronavirus Pneumonia; Hydroxychloroquine Sulfate; Treatment Effect ;

Classification: R563.1

© China Know.com's exclusive online launch is forbidden to reprint or extract without permission.

HTML reading CAJ download PDF download

Downloads: 481 Pages: 8 Size: 464K



Mobile reading this

to download and install



HTML reading CAJ download PDF download

Downloads: 481 Pages: 8 Size: 464K

Knowledge node
Basic Information
Summary
fund
Key words
Classification number
Knowledge network
Citation network
Associate Author
similar article
Related Fund Literature

Citation Network Reference Citation Map

Co-citing documents (0)

Secondary references (0) References (1) Node Literature Citations (0) Seconda

Co-cited documents (0)



[About Us](#) [CNKI Honor](#) [Copyright Announcement](#) [Customer Service](#) [Online Consultation](#) [User Suggestion](#) [HowNet Promotion](#)

Reader service

- Buy Zhinet Card
- Recharge Center
- My CNKI
- Help Center

CNKI Common Software

- Download**
- CAJViewer browser
- HowNet research study (formerly E-Study)
- books the desktop search software

special service

- Mobile HowNet
- Magazine Subscription
- Digital Publication
- Subscription

Customer Service

- Consulting**
- Order card hotline: 400-819-9993
- Hotline: 400-810-9888
- Online Consultation: help.cnki.net
- mail advice: help@cnki.net
- customer service Weibo:

Beijing ICP Certificate No. 040,431 online p
 license (total) net issuance of certificates (B
 An Reserved 11010802020460 Beijing publ
 © 1998-2019 China HowNet (the CNKI)
 "China Academic Journal (CD)" Electronic 1
 magazine
 KDN platform basic technology is led
 current IP: 101.186.194.215